SL
CRL icon

Salomon & Ludwin’s Charles River Laboratories CRL Stock Holding History

Salomon & Ludwin’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6K Hold
61
– – ﹤0.01% 1495
2025
Q4 		$12.7K Hold
61
– – ﹤0.01% 1275
2025
Q3 		$10.8K Buy
+61
New +$9.69K ﹤0.01% 1247

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Salomon & Ludwin's CRL Position: Q1 2026 in Review

Salomon & Ludwin held its Charles River Laboratories (CRL) position steady in Q1 2026 at 61 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1495.

Salomon & Ludwin first reported a position in CRL in Q3 2025 and has held it in 3 quarters since. The position peaked at $12.7K in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Salomon & Ludwin held 61 shares of Charles River Laboratories worth $10.6K as of Q1 2026.
  • Salomon & Ludwin left its Charles River Laboratories share count unchanged in Q1 2026.
  • Charles River Laboratories made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #1495 holding.
  • Salomon & Ludwin first reported a position in Charles River Laboratories in Q3 2025 and has held it in 3 quarters since.
  • Salomon & Ludwin's Charles River Laboratories position peaked at $12.7K in Q4 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.